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Abstract
Background: The proto-oncogene pituitary tumor-transforming gene (PTTG) has been shown to
be abundantly overexpressed in a large variety of neoplasms likely promoting neo-vascularization
and tumor invasiveness. In this study, we investigated a potential role for PTTG mRNA expression
as a marker to evaluate the future clinical outcome of patients diagnosed with primary cancer of
the head and neck.
Methods: Tumor samples derived from primary tumors of 89 patients suffering from a squamous
cell carcinoma were analyzed for PTTG mRNA-expression and compared to corresponding
unaffected tissue. Expression levels were correlated to standard clinico-pathological parameters
based on a five year observation period.
Results: In almost all 89 tumor samples PTTG was found to be overexpressed (median fold
increase: 2.1) when compared to the unaffected tissue specimens derived from the same patient.
The nodal stage correlated with PTTG transcript levels with significant differences between pN0
(median expression: 1.32) and pN+ (median expression: 2.12; P = 0.016). In patients who developed
a tumor recurrence we detected a significantly higher PTTG expression in primary tumors (median
expression: 2.63) when compared to patients who did not develop a tumor recurrence (median
expression: 1.29; P = 0.009). Since the median expression of PTTG in patients with tumor stage T1/
2N0M0 that received surgery alone without tumor recurrence was 0.94 versus 3.82 in patients
suffering from a tumor recurrence (P = 0.006), PTTG expression might provide a feasible mean of
predicting tumor recurrence.
Conclusion: Elevated PTTG transcript levels might be used as a prognostic biomarker for future
clinical outcome (i.e. recurrence) in primary squamous cell carcinomas of the head and neck,
especially in early stages of tumor development.
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Background
Pituitary tumor-transforming gene (PTTG) was originally
identified in rat pituitary tumors by differential display
PCR. Stable transfection in mouse NIH-3T3 fibroblasts
induced cellular transformation in vitro and led to tumor
formation in athymic nude mice [1]. Further functional
analysis identified PTTG as human securin, the functional
analogue to the Pds1p protein of budding yeast and the
Cut2p protein of fission yeast [2]. In yeast, the securins
Pds1p and Cut2p bind to separins (Esp1p or Cut1p
respectively), thereby inhibiting sister chromatid separa-
tion until degradation of securins by the anaphase pro-
moting complex (APC) at the metaphase to anaphase
transition. The release of active separins leads to the deg-
radation of a distinct protein of the multi-protein com-
plex which holds sister chromatids together since DNA
duplication in S-phase [3]. Furthermore, as confirmed by
preliminary investigations in mammalian cells, the
expression levels of PTTG transcripts and protein are
upregulated in rapidly proliferating cells and in a variety
of solid tumors including carcinomas of the lung, breast,
melanomas, hematopoietic neoplasias and tumor cell
lines [4,5]. Moreover, PTTG-protein levels fluctuated dur-
ing the cell cycle, reaching a peak in mitosis [6,7].
Worldwide, more than half a million new cases of squa-
mous cell carcinomas of the upper aerodigestive tract are
annually diagnosed. Up to 90% of these individuals are
inhaling tobacco smoke and/or ingest alcohol on a regu-
lar basis [8]. Most of these patients are introduced to clin-
ical care with an UICC (Union International Contre
Cancer) stage III or IV, and show an overall life expectancy
of less than 40%, despite multimodal treatment strategies
like surgery, radiation and chemotherapy [9]. Currently,
the most important prognostic factor of head and neck
squamous cell carcinoma (HNSCC) is the pathological
stage, especially the nodal stage (pN). Due to the fact that
tumors of the same stage can show different biological
behaviors resulting in different prognoses, we focused on
new biological factors to improve the tools for treatment
and prognosis of HNSCC. Presently, a set of biological
parameters for prognostic evaluation of HNSCC has been
described such as p53, epidermal growth factor receptor,
cyclin D1 and Polo-like kinase mRNA and protein expres-
sion, which we found recently as independent markers for
the survival of patients with HNSCCs [10-12]. Consider-
ing the probabilities of tumor recurrences in early stages
of tumor development (pT1/2N0M0), most of these
parameters do not suffice for predicting clinical outcome.
Recent findings suggest that the expression of pituitary
tumor transforming gene (PTTG) might serve as a marker
for tumor invasiveness in colorectal cancer [13] as well as
a marker for lymph node invasion of breast cancer [14]
and small and non small cell lung cancer [15]. Based on
these observations, we investigated the prognostic value
of pituitary-tumor transforming gene (PTTG) expression
in squamous cell carcinomas of the head and neck.
In the present study, we examined the PTTG mRNA
expression of a large number of HNSCC tumors and com-
pared those to PTTG mRNA expression levels in micro-
scopically unaffected mucosa of the same patients.
Interestingly, we were able to detect elevated PTTG mRNA
levels in the vast majority of HNSCC and more impor-
tantly, PTTG levels were related to the tumor stage. In
summary, on the basis of a 5-year observation period,
PTTG mRNA expression in the primary tumor improves
the prediction of tumor recurrence especially in early
stages of tumor development.
Methods
Patients and tumor samples
Analyses were performed on tumor samples of 89 patients
with HNSCC (78 male and 11 female) who were treated
at the Department of Otolaryngology of the J. W. Goethe-
University, School of Medicine, Frankfurt am Main, Ger-
many from 1987 to 1997. Patients were diagnosed with
either oropharyngeal carcinomas (n = 66) or larynx carci-
nomas (n = 23). The median age was 54 years with a range
from 22–84 years. All patients were smokers and ingested
alcohol on a regular basis. Staging of patients prior to
treatment included computed tomography scan of the
head und neck, chest x-ray and sonography of the neck
and abdomen as well as endoscopy of the upper aerodi-
gestive tract, oesophagoscopy and bronchoscopy. All 89
patients underwent a complete resection of the primary
tumor and unilateral elective neck dissection of the clini-
cally negative neck. In case of clinically positive lymph
nodes, unilateral or bilateral neck dissection was per-
formed, depending on the involvement of lymph nodes.
All neck dissections were carried out as modified radical
neck dissections type III [16]. Vital tumor probes were
removed from the primary site and microscopically nor-
mal tissues were taken approximately 5 cm apart from the
tumor margins. Tissue samples were immediately frozen
in liquid nitrogen and stored at -80°C. In line with histo-
logical criteria, all tumors were classified as HNSCCs,
WHO grading I-III. The post surgical stage of each patient
was classified in accordance to the tumor-node-metastasis
system. Most patients were diagnosed as stage IV (T3-
4N2M0, n = 36; T3-4N3M0, n = 19), while other patients
were stage III (T3N1M0, n = 9), stage II (T2N0M0, n = 15)
and stage I (T1N0M0, n = 10). Patients of stages I and II
were submitted to surgery alone, patients of stages III und
IV underwent surgery and postoperative radiotherapy.
Standard radiation schedule was used with 2 Gy fractions
given as once-a-day treatment of a total dose of 70 Gy
applied to the primary region and the neck. Chemother-
apy was given nonconcomitantly, applying three cycles of
cisplatinum (20 mg/m2/day) and 5-fluorouracil (1000BMC Cancer 2006, 6:242 http://www.biomedcentral.com/1471-2407/6/242
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mg/m2/day), according to a standard schedule [17].
Tumor recurrences were treated chemotherapeutically
with the same regimen until no response or progressive
disease was detected in two dimensions by computed
tomography scan. Routine investigations were conducted
over a period of 5 years post therapeutically, which
involved clinical investigation, sonography and com-
puted tomography of the head and neck as well as sonog-
raphy of the abdomen and chest x-ray. The majority of
patients, who suffered from recurrences developed loco
regional metastasis (n = 46), while only few patients
exhibited lung metastases (n = 3). The median time to
recurrence was 8.5 months after treatment with a range
between 2 and 61 months. Survival time of terminal
patients ranged from 1–80 months with a median of 15.5
months. The median quality of life index during the
observation period with reference to the Eastern Cooper-
ative Oncology Group scale (ECOG) was 3. The hospital
local ethics committee approval was obtained for the
study.
RNA-isolation and northern blot analysis
Tumor sample preparation
Tumor samples were stored in liquid nitrogen immedi-
ately after excision. A sample of 500 – 1000 mg was
homogenized in a guanidinium isothiocyanate solution.
RNA was prepared by ultracentrifugation at 125.000 g
through a 5.7 M CsCl2 cushion. 2 μg total RNA were sep-
arated in a denaturing 1.5% agarose/2% formaldehyde
gel, RNA quality was confirmed by ethidium-bromide
staining before RNA was transferred to nylon membranes
which were subsequently probed with digoxigenin
labeled PTTG full-length cRNA probe.
Probes for northern blotting
A reverse-transcription PCR using Expand Reverse Tran-
scriptase according to manufacturers instructions was per-
formed (all solutions and enzymes for PCR protocols
were obtained from Roche). The cDNA template was used
in a standard PCR with a sequence-specific 5'-primer (5'-
CAG AAT GGC TAC TCT GAT CTA TGT TGA TAA G-3')
and the specific 3'-primer linked to T-7 polymerase pro-
moter (5'-TAA TAC GAC TCA CTA TAG GGG CCC AGC
TGA AAC TT-3'; underlined T-7 promoter sequence) using
Expand High Fidelity PCR System. The probes were gener-
ated using the PCR product after sequencing as template
for transcription by T-7 polymerase with digoxigenin
labeled dUTP.
Hybridization and detection of RNA products
The prehybridizytion/hybridization steps were performed
at 68°C for three hours/over night in DIG Easy Hyb solu-
tion (Roche). The membranes were washed twice under
high stringent conditions in 0.1 × SSC/0.1% SDS and
products subsequently detected by immunological meth-
ods using alkaline phosphatase conjugated anti-DIG-Fab
fragments and chemiluminescence reagent CDPStar
according to the manufacturers protocol (Roche). After
detection, membranes were stripped and reprobed with β-
Actin mRNA Probe (Roche).
Detection of mRNA expression level and statistics for tumor samples
The intensity of the specific chemiluminescence signal
was quantified using Kodak 440 CF documentation sys-
tem running the 1D image analysis software. A rectangle
was drawn around the specific signal and intensity was
calculated by subtracting the mean of the background sig-
nal (Kodak, Rochester, NY). The RNA load was normal-
ized to β-Actin  and the quotient (density units PTTG)/
(density units β-Actin) was used for the statistical analyses
as described previously [10]. All analyses were performed
using the software package SPSS 9.0 for Windows.
Immunohistochemistry
Antigen retrieval was performed on 4 μm tissue sections
by boiling in 0.01 Mol citrate buffer (pH 6.0) for 20 min-
utes. Sections were incubated with polyclonal rabbit anti-
PTTG (Zymed) (or rabbit preimmuneserum for control)
for 60 minutes at 37°C, subsequently washed in Tris-
buffered saline (TBS) pH 7.4 and incubated with alkaline
phosphatase labeled mouse anti rabbit antibody (DAKO),
followed by neufuchsin detection (DAKO). All sections
were counterstained with hematoxylin.
Results
PTTG mRNA is overexpressed in squamous cell carcinomas 
of the head and neck
Northern blot analysis revealed that PTTG mRNA was
hardly detectable in normal adult mucosa of the upper
aerodigestive tract, as well as microscopically unaffected
mucosa of tumor patients. In contrast to these unaffected
tissue specimens a prominent signal of approximately 0.9
kb, representing the PTTG transcript, was detected in the
vast majority of 89 tumors derived from patients with
HNSCC, indicating that PTTG mRNA is overexpressed in
these specimens (Fig 1a). The normalized PTTG expres-
sion ranged from 0.00 up to 18.67 density units (mean:
3.22 d.u.; median: 1.59 d.u.) in tumor tissue samples (Fig-
ure 1b) and from 0.00 to 1.56 d.u (mean: 1.23 d.u.;
median: 0.74 d.u.) in the corresponding normal mucosa
(median fold increase: 2.1 when compared to the unaf-
fected tissue specimens derived from the same patient).
The Wilcoxon test for comparison of tumor expression
levels versus unaffected normal sample levels had an over-
all significance of P < 0.05 (n = 89).
Expression levels of PTTG correlate with tumor staging 
parameters
In order to determine whether PTTG expression levels cor-
relate with clinical parameters, we performed a Kruskal-BMC Cancer 2006, 6:242 http://www.biomedcentral.com/1471-2407/6/242
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Wallis analysis, which revealed that PTTG mRNA levels
correlate with the pathological T stage (pT; P = 0.013, an
overview of significant correlations found in this study is
given in Table 1). Furthermore, pN-stage, the most impor-
tant prognosis factor in head and neck cancer, correlated
with PTTG expression levels with an overall significance of
P ≤ 0.021 (Figure 2a). Moreover, highly significant (P =
0.016) differences between pN0 and pN+ were observed
(median fold increase: 2.1) (Figure 2b and Table 1).
PTTG is an indicator for the risk of tumor recurrence
We next investigated whether PTTG mRNA expression of
primary tumors can be correlated with the development
of recurrences. Based on an observation period of 5 years
Expression of PTTG mRNA in HNSCC tumor samples Figure 1
Expression of PTTG mRNA in HNSCC tumor samples. Total RNA (2 μg) underwent electrophoresis, transferred to 
positively charged nylon membranes and probed with PTTG specific probe (TA = T2N0M0/no recurrence, TB = T4N1M0/
recurrence, TC = T3N2M0/no recurrence, TD = T2N0M0/recurrence, N indicates the corresponding normal tissue). Bottom 
of panel (a) shows the corresponding β-Actin signal after stripping and re-hybridization procedure. (b) Distribution of normal-
ized PTTG expression levels in all (n = 89) analyzed tumor samples.
(a)
(b)BMC Cancer 2006, 6:242 http://www.biomedcentral.com/1471-2407/6/242
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after primary therapy, patients who developed tumor
recurrences had significantly higher PTTG expression lev-
els in their primary tumors when compared to those
patients who did not develop a tumor recurrence (Mann
Whitney U test, P = 0.009). The median expression level
of recurrent tumors (n = 49) was 2.63 d.u., with a range
from 0.74 to 18.67 d.u., whereas in non-recurrent tumors,
PTTG expression was detectable only within a range of
0.00 to 8.37 d.u. with a median of 1.29 d.u. (Figure 3a).
Additionally, by using the median cut off level, we
revealed that 68% of the patients exhibiting PTTG =
median (1.59 d.u.) developed a tumor recurrence while
this was true for only 39% of those patients who exhibited
PTTG < median. Moreover, for the clinical more homoge-
nous pN0 group (n = 25, all Patients were T1/2N0M0 and
received surgery as single therapy), the median PTTG
expression level of recurrent carcinomas (n = 8) was 3.82
d.u. (range: 1.90 to 5.29 d.u.) in comparison to the
median level of 0.94 d.u. (range: 0.00 to 2.54 d.u.) of non-
recurrent tumors (n = 17). Since this difference was highly
significant (P  = 0.006), we hypothesized that PTTG
expression levels may serve as a prognostic factor to pre-
dict different recurrence probabilities within the pN0
population (Figure 3b). This notion was confirmed by
using the median cut off level (1.32 d.u.) of PTTG mRNA
expression in the pN0 group. In this group, only a single
patient (n = 17), whose primary tumor exhibited PTTG
expression < median, developed a tumor recurrence. By
contrast, all 8 patients from the pN0 group, who showed
PTTG mRNA expression values = median in their primary
tumors, developed a tumor recurrence. Subsequently, we
performed a series of immunohistochemical analyses to
further substantiate our findings and to correlate them to
clinically more applicable immunohistochemical meth-
ods,. Expectedly, for pT1/2N0M0 patients, we could
detect a strong immunoreactivity of primary tumors, espe-
cially in tumors of patients who acquire a tumor recur-
rence. In contrast, primary tumor samples from patients,
who did not develop a tumor recurrence, exhibited only
weak immunoreactivity (Figure 4).
Discussion
Estimation of prognosis and biological behavior of head
and neck cancer is primarily based on clinicopathological
parameters, mainly on tumor site and regional lymph
node involvement. However, it is well known that tumors
of the same clinicopathological stage can behave differ-
ently, especially in regard to the risk of tumor recurrences.
Therefore, current work is focusing on the evaluation of
molecular parameters to differentiate and complete the
prognostic statement, which is critical to refine and
improve treatment strategies [12]. The pituitary tumor-
transforming gene is a recently characterized oncogene,
originally isolated by its differential expression in pitui-
tary tumor cells [1]. PTTG mRNA and protein is overex-
pressed in a variety of carcinomas [4,6,14,15], suggesting
that PTTG may be involved in tumorigenesis. In addition
to its function as human securin during the cell cycle,
recent studies convincingly demonstrate that PTTG acts as
Distribution of PTTG expression in primary tumors with dif- ferent pN stages Figure 2
Distribution of PTTG expression in primary tumors 
with different pN stages. Boxplot shows PTTG expres-
sion of all analyzed primary tumors (n = 89) grouped to their 
corresponding pN-stages (a). The pN-stage correlated to 
PTTG expression level with a significance of P = 0.021. 
Thereby significant (P = 0.016) differences between the pN0 
(n = 25, negative) and pN+ (n = 64, positive) staged patients 
could be detected (b).
(a)
(b)
Table 1: Overview of significant correlations between PTTG 
overexpression in primary tumors and standard clinico-
pathological parameters found.
Significant correlations Level of significance
pT 0.013 (n = 89)
pN 0.021 (n = 89)
Tumor recurrence 0.009 (n = 89)
pN0 versus pN+ 0.016 (n = 89)
Tumor recurrence in T1/2N0M0 group 0.006 (n = 25)BMC Cancer 2006, 6:242 http://www.biomedcentral.com/1471-2407/6/242
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a transcriptional activator. This function seems to be reg-
ulated by the activation of the mitogen-activated protein
kinase cascade (MAPK) by epidermal growth factor (EGF).
The interaction of PTTG with activated MAP kinase kinase
(MEK-1) is crucial for the transactivation function of
PTTG [18]. The MAPK-pathway is known to be important
in the regulation of cell growth, apoptosis and differenti-
ation. Numerous studies reported a correlation between
over-expression of the epidermal growth factor receptor
(EGFR, c-erbB1) and poor prognosis in head and neck
squamous cell carcinomas [19]. Moreover, it has been
demonstrated that MAPK activation regulates rat PTTG
translocation into the nucleus where it is able to transcrip-
tionally activate the oncogene c-myc in vitro. [20]. This
might be of special interest, because c-myc is known to
play a critical role in the control of cellular proliferation
and deregulation of c-myc is associated with a variety of
tumors. In human cancer, overexpression of c-myc pro-
tein stimulates cell cycle progression, leads to transforma-
tion and blocks differentiation [21]. The induction of c-
myc  expression by overexpression of PTTG results in
increased cell proliferation and colony formation,
strengthening the idea of PTTG playing an important role
in the regulation of cell growth [18]. Furthermore, PTTG
also induces basic fibroblast-growth factor (bFGF) secre-
tion, indicating a role of PTTG in tumor angiogenesis
[13,22,23] that is essentially required for tumor survival.
Altogether, these observations underline the role of PTTG
in development and maintenance of neoplastic processes.
Conclusion
In this study, we examined 89 patients with HNSCC and
compared the PTTG expression of their primary tumors to
unaffected tissues of the same patient. In comparison with
normal mucosa of the upper aerodigestive tract and in
microscopically unaffected mucosa, we found PTTG
mRNA to be overexpressed in the vast majority of
HNSCCs. Moreover, the observation that metastatic as
well as recurrent HNSCC exhibited a significantly higher
PTTG expression than non-metastatic and non-recurrent
primary tumors suggests, that determination of the PTTG
status might provide feasible means to predict the meta-
static potential of a tumor. This is especially of clinical
interest in an early clinicopathological stage (N0, pN0),
where the determination of PTTG expression in the pri-
mary tumor in addition to conventional staging may con-
tribute to evaluate the risk of a tumor recurrence more
precisely. In our study, PTTG expression did not correlate
to any other standard clinico-pathological parameters or
to survival of patients.
Although loss of yeast securin Pds1p or Drosophila
securin pimples is lethal [24,25], mice lacking PTTG are
viable and fertile. PTTG-/- fibroblasts exhibit dysfunction
in the cell cycle [26,27]. Thus, besides its transcriptional
regulation of target genes, like c-myc, PTTG has essential
functions in promoting cell cycle events. Being aware of
these observations and given the fact that overexpression
of PTTG promotes cellular transformation [1], we suggest
that PTTG might represent a promising target to inhibit
tumor cell growth, thereby improving treatment strategies
PTTG mRNA expression in primary tumors of patients with  tumor recurrences Figure 3
PTTG mRNA expression in primary tumors of 
patients with tumor recurrences. (a) Boxplot shows the 
PTTG expression in primary tumors of all patients (n = 89) 
who suffered from a recurrence (positive, n = 49) versus the 
patients who did not develop a recurrence (negative, n = 40) 
within the 5-years observation period (P = 0.009). Boxplot 
(b) shows the distribution of PTTG mRNA levels in primary 
tumors in comparison to those levels in tumors of pN0 (n = 
25) staged patients with (positive) and without (negative) a 
tumor recurrence (P = 0.006).
(a)
(b)BMC Cancer 2006, 6:242 http://www.biomedcentral.com/1471-2407/6/242
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Immunhistochemical analysis of PTTG Figure 4
Immunhistochemical analysis of PTTG. Exemplary PTTG staining of a primary tumor of a patient (pT1N0M0), who did 
not develop a tumor recurrence within the observation period (a). Staining of a primary tumor of a patient (pT1N0M0) who 
developed a tumor recurrence 24 months after primary tumor resection (c). (e) PTTG staining in the tumor recurrence of the 
same patient. (b, d and f) corresponding control sections after IgG staining.BMC Cancer 2006, 6:242 http://www.biomedcentral.com/1471-2407/6/242
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for patients with a high probability of developing a tumor
recurrence [28].
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